Advancing Knowledge. Enhancing Care.
Advancing Knowledge. Enhancing Care.

Psoriasis News

the latest news from ipc, industry and others

Industry

Displaying 1 to 10 of 31 Posts . Displaying 10 of Posts . Page of 4 . Go To Page: . Per Page: . . . View All Sort By: .

Grand Rounds tutorial on IPC's psoriasis severity reclassification

The AbbVie program features IPC Board Member Bruce Strober’s Grand Rounds, a tutorial explaining the current method of measuring the severity of psoriasis, why this limits proper care and treatment for psoriasis patients, how IPC’s Disease Severity Reclassification Project solves these problems, and how clinicians can implement this new classification method.

Read More

INSIDE LOOK campaign raises awareness about plaque psoriasis

Amgen and Otezla® (apremilast) have partnered with Allan Avendaño, makeup artist to Hollywood A-listers, for the INSIDE LOOK campaign to share his journey living with plaque psoriasis and the difficulties of being in his demanding role and dealing with a chronic skin condition.

Read More

Dermavant submits New Drug Application to FDA for tapinarof cream for the treatment plaque psoriasis

Dermavant Sciences announced on June 3, 2021 that it has submitted a New Drug Application to the U.S. Food and Drug Administration for tapinarof for the treatment of mild, moderate and severe plaque psoriasis in adult patients.

Read More

Serie de Videos Sobre la Reclasificación de la Gravedad de la Psoriasis del IPC

Conozca cómo se mide actualmente la gravedad de la psoriasis y por qué es necesario un cambio, cómo el IPC organizó el proceso Delphi que se utilizó para redefinir la clasificación de la gravedad, las implicaciones y los efectos que tiene el resultado en los proveedores de tratamiento de la psoriasis y los pacientes con psoriasis y, en última instancia, cómo los pacientes se beneficiarán de esto. esfuerzo.

Read More

Video Series on IPC’s Psoriasis Severity Reclassification

Learn how psoriasis severity is currently measured and why a change is necessary, how IPC organized the Delphi process that was used to redefine severity classification, implications and effects the output has on psoriasis treatment providers and psoriasis patients, and ultimately how patients will benefit from this endeavor.

Read More

Janssen Phase-3 TREMFYA® Clinical Trial

Janssen Pharmaceutical Companies of Johnson & Johnson published the long-term data of the third phase of the DISCOVER-2a study.

Read More

Sun Pharma Phase-3 ILUMYA® Clinical Trial

Sun Pharmaceutical Industries Inc. announces results from their five-year Phase-3 efficacy and safety clinical trial for ILUMYA®(tildrakizumab-asmn) based on a pooled analysis of the ReSURFACE 1 and ReSURFACE 2 extension.

Read More

New Corporate Member: Dermavant

IPC welcomes Dermavant as a new 2021 corporate member.

Read More

Lilly's Taltz® (ixekizumab) Receives U.S. FDA Approval for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

Lilly's TALTZ® (IXEKIZUMAB) receives U.S. FDA approval for the treatment of pediatric patients with moderate to severe plaque psoriasis

Read More

AbbVie Launches Let Me Be Clear to Empower People with Psoriasis to Speak Up and Seek Freedom from Their Disease

AbbVie, a research-based global biopharmaceutical company, today announced the launch of Let Me Be Clear, an empowerment platform for people living with psoriasis. The initiative, which launches on World Psoriasis Day, invites people living with psoriasis to share their story, discuss what freedom from psoriasis would mean to them and access tools to have clear and informed conversations with their physicians.

Read More

Stay informed

Join the email list to receive the latest information on psoriasis meetings, manuscripts and research.
SUBSCRIBE

now available

COVID-19 Psoriasis Resource Center

Information from around the world on psoriasis and coronavirus to assist dermatologists and the patients they serve

explore now

 

We use cookies on this site to enhance your online experience. By continuing to use this site, you agree to accept cookies.
OK